Estrogen receptors and E2F transcription factors are the key players of two nuclear signaling pathways which exert a major role in oncogenesis, particularly in the mammary gland. Different levels of dialogue between these two pathways have been deciphered and deregulation of the E2F pathway has been shown to impact the response of breast cancer cells to endocrine therapies. The present review focuses on the transcriptional coregulator RIP140/NRIP1 which is involved in several regulatory feed-back loops and inhibitory cross-talks between different nuclear signaling pathways. RIP140 regulates the transactivation potential of estrogen receptors and E2Fs and is also a direct transcriptional target of these transcription factors. Published data highlight the complex regulation of RIP140 expression at the transcriptional level and its potential role in transcription cross-talks. Indeed, a subtle regulation of RIP140 expression levels has important consequences on other transcription networks targeted by this coregulator. Another level of regulation implies titration mechanisms by which activation of a pathway leads to sequestration of the RIP140 protein and thus impinges other gene regulatory circuitries. Altogether, RIP140 occupies a place of choice in the dialogue between nuclear receptors and E2Fs, which could be highly relevant in various human pathologies such as cancer or metabolic diseases.
Dahlman-Wright, K., Cavailles, V., Fuqua, S.A., Jordan, V.C., Katzenellenbogen, J.A., Korach, K.S., Maggi, A., Muramatsu, M., Parker, M.G. and Gustafsson, J.-A. (2006) International Union of Pharmacology. LXIV. Estrogen receptors. Pharmacological Reviews, 58, 773-781. http://dx.doi.org/10.1124/pr.58.4.8
Manavathi, B., Dey, O., Gajulapalli, V.N.R., Bhatia, R.S., Bugide, S. and Kumar, R. (2013) Derailed estrogen signaling and breast cancer: An authentic couple. Endocrine Reviews, 34, 1-32. http://dx.doi.org/10.1210/er.2011-1057
Obiorah, I. and Jordan, V.C. (2011) Progress in endocrine approaches to the treatment and prevention of breast cancer. Maturitas, 70, 315-321. http://dx.doi.org/10.1016/j.maturitas.2011.09.006
Levin, E.R. (2011) Minireview: Extranuclear steroid receptors: Roles in modulation of cell functions. Molecular Endocrinology (Baltimore, Md.), 25, 377-384. http://dx.doi.org/10.1210/me.2010-0284
Le Romancer, M., Poulard, C., Cohen, P., Sentis, S., Renoir, J.-M. and Corbo, L. (2011) Cracking the estrogen receptor’s posttranslational code in breast tumors. Endocrine Reviews, 32, 597-622. http://dx.doi.org/10.1210/er.2010-0016
Chen, H.-Z., Tsai, S.-Y. and Leone, G. (2009) Emerging roles of E2Fs in cancer: An exit from cell cycle control. Nature Reviews Cancer, 9, 785-797. http://dx.doi.org/10.1038/nrc2696
Indovina, P., Marcelli, E., Casini, N., Rizzo, V. and Giordano, A. (2013) Emerging roles of RB family: New defense mechanisms against tumor progression. Journal of Cellular Physiology, 228, 525-535. http://dx.doi.org/10.1002/jcp.24170
Du, W. and Searle, J.S. (2009) The rb pathway and cancer therapeutics. Current Drug Targets, 10, 581-589. http://dx.doi.org/10.2174/138945009788680392
Macaluso, M., Cinti, C., Russo, G., Russo, A. and Giordano, A. (2003) pRb2/p130-E2F4/5-HDAC1-SUV39H1-p300 and pRb2/p130-E2F4/5-HDAC1-SUV39H1-DNMT1 multimolecular complexes mediate the transcription of estrogen receptor-alpha in breast cancer. Oncogene, 22, 3511-3517. http://dx.doi.org/10.1038/sj.onc.1206578
Umemura, S., Shirane, M., Takekoshi, S., Kusakabe, T., Itoh, J., Egashira, N., Tokuda, Y., Mori, K. and Osamura, Y.R. (2009) Overexpression of E2F-5 correlates with a pathological basal phenotype and a worse clinical outcome. British Journal of Cancer, 100, 764-771. http://dx.doi.org/10.1038/sj.bjc.6604900
Mussi, P., Yu, C., O’Malley, B.W. and Xu, J. (2006) Stimulation of steroid receptor coactivator-3 (SRC-3) gene overexpression by a positive regulatory loop of E2F1 and SRC-3. Molecular Endocrinology (Baltimore, Md.), 20, 3105-3119. http://dx.doi.org/10.1210/me.2005-0522
Batsché, E., Desroches, J., Bilodeau, S., Gauthier, Y. and Drouin, J. (2005) Rb enhances p160/SRC coactivator-dependent activity of nuclear receptors and hormone responsiveness. The Journal of Biological Chemistry, 280, 19746-19756. http://dx.doi.org/10.1074/jbc.M413428200
Macaluso, M., Montanari, M., Noto, P.B., Gregorio, V., Surmacz, E. and Giordano, A. (2006) Nuclear and cytoplasmic interaction of pRb2/p130 and ER-beta in MCF-7 breast cancer cells. Annals of Oncological Office Journal of European Society for Medical Oncology ESMO, 17, vii27-vii29. http://dx.doi.org/10.1093/annonc/mdl945
Abbondanza, C., Medici, N., Nigro, V., Rossi, V., Gallo, L., Piluso, G., Belsito, A., Roscigno, A., Bontempo, P., Puca, A.A., Molinari, A.M., Moncharmont, B. and Puca, G.A. (2000) The retinoblastoma-interacting zinc-finger protein RIZ is a downstream effector of estrogen action. Proceedings of the National Academy of Sciences of the USA, 97, 3130-3135. http://dx.doi.org/10.1073/pnas.97.7.3130
Chua, S.S., Ma, Z., Ngan, E. and Tsai, S.Y. (2004) Cdc25B as a steroid receptor coactivator. Vitamins & Hormones, 68, 231-256. http://dx.doi.org/10.1016/S0083-6729(04)68008-3
Weigel, N.L. and Moore, N.L. (2007) Cyclins, cyclin dependent kinases, and regulation of steroid receptor action. Molecular and Cellular Endocrinology, 265-266, 157-161. http://dx.doi.org/10.1016/j.mce.2006.12.013
Ngwenya, S. and Safe, S. (2003) Cell context-dependent differences in the induction of E2F-1 gene expression by 17β-estradiol in MCF-7 and ZR-75 cells. Endocrinology, 144, 1675-1685. http://dx.doi.org/10.1210/en.2002-0009
Zhou, W., Srinivasan, S., Nawaz, Z. and Slingerland, J.M. (2013) ERα, SKP2 and E2F-1 form a feed forward loop driving late ERα targets and G1 cell cycle progression. Oncogene, in press. http://dx.doi.org/10.1038/onc.2013.197
Stender, J.D., Frasor, J., Komm, B., Chang, K.C.N., Kraus, W.L. and Katzenellenbogen, B.S. (2007) Estrogen-regulated gene networks in human breast cancer cells: Involvement of E2F1 in the regulation of cell proliferation. Molecular Endocrinology (Baltimore, Md.), 21, 2112-2123. http://dx.doi.org/10.1210/me.2006-0474
Bourdeau, V., Deschênes, J., Laperrière, D., Aid, M., White, J.H. and Mader, S. (2008) Mechanisms of primary and secondary estrogen target gene regulation in breast cancer cells. Nucleic Acids Research, 36, 76-93. http://dx.doi.org/10.1093/nar/gkm945
Tu, Z., Prajapati, S., Park, K.-J., Kelly, N.J., Yamamoto, Y. and Gaynor, R.B. (2006) IKK alpha regulates estrogen-induced cell cycle progression by modulating E2F1 expression. The Journal of Biological Chemistry, 281, 6699-6706. http://dx.doi.org/10.1074/jbc.M512439200
Hartman, J., Müller, P., Foster, J.S., Wimalasena, J., Gustafsson, J.-A. and Strom, A. (2004) HES-1 inhibits 17beta-estradiol and heregulin-beta1-mediated upregulation of E2F-1. Oncogene, 23, 8826-8833. http://dx.doi.org/10.1038/sj.onc.1208139
Planas-Silva, M.D. and Weinberg, R.A. (1997) Estrogen-dependent cyclin E-cdk2 activation through p21 redistribution. Molecular and Cellular Biology, 17, 4059-4069.
Prall, O.W., Sarcevic, B., Musgrove, E.A., Watts, C.K. and Sutherland, R.L. (1997) Estrogen-induced activation of Cdk4 and Cdk2 during G1-S phase progression is accompanied by increased cyclin D1 expression and decreased cyclin-dependent kinase inhibitor association with cyclin E-Cdk2. The Journal of Biological Chemistry, 272, 10882-10894. http://dx.doi.org/10.1074/jbc.272.16.10882
Foster, J.S., Henley, D.C., Ahamed, S. and Wimalasena, J. (2001) Estrogens and cell-cycle regulation in breast cancer. Trends in Endocrinology & Metabolism TEM, 12, 320-327. http://dx.doi.org/10.1016/S1043-2760(01)00436-2
Morris, L., Allen, K.E. and La Thangue, N.B. (2000) Regulation of E2F transcription by cyclin E-Cdk2 kinase mediated through p300/CBP co-activators. Nature Cell Biology, 2, 232-239. http://dx.doi.org/10.1038/35041123
Martinez-Balbas, M.A., Bauer, U.M., Nielsen, S.J., Brehm, A. and Kouzarides, T. (2000) Regulation of E2F1 activity by acetylation. EMBO Journal, 19, 662-671. http://dx.doi.org/10.1093/emboj/19.4.662
Kong, H.J., Yu, H.J., Hong, S., Park, M.J., Choi, Y.H., An, W.G., Lee, J.W. and Cheong, J. (2003) Interaction and functional cooperation of the cancer-amplified transcriptional coactivator activating signal cointegrator-2 and E2F-1 in cell proliferation. Molecular Cancer Research MCR, 1, 948-958.
Louie, M.C., Zou, J.X., Rabinovich, A. and Chen, H.W. (2004) ACTR/AIB1 functions as an E2F1 coactivator to promote breast cancer cell proliferation and antiestrogen resistance. Molecular and Cellular Biology, 24, 5157-5171. http://dx.doi.org/10.1128/MCB.24.12.5157-5171.2004
Musgrove, E.A. and Sutherland, R.L. (2009) Biological determinants of endocrine resistance in breast cancer. Nature Reviews Cancer, 9, 631-643.
Jordan, V.C. and O’Malley, B.W. (2007) Selective estrogen-receptor modulators and antihormonal resistance in breast cancer. Journal of Clinical Oncology Office and American Society of Clinical Oncology, 25, 5815-5824. http://dx.doi.org/10.1200/JCO.2007.11.3886
Wilcken, N.R., Sarcevic, B., Musgrove, E.A. and Sutherland, R.L. (1996) Differential effects of retinoids and antiestrogens on cell cycle progression and cell cycle regulatory genes in human breast cancer cells. Cell Growth & Differentiation Journal of Molecular Biology American Association for Cancer Research, 7, 65-74.
Carroll, J.S., Prall, O.W., Musgrove, E.A. and Sutherland, R.L. (2000) A pure estrogen antagonist inhibits cyclin ECdk2 activity in MCF-7 breast cancer cells and induces accumulation of p130-E2F4 complexes characteristic of quiescence. The Journal of Biological Chemistry, 275, 38221-38229. http://dx.doi.org/10.1074/jbc.M004424200
Bosco, E.E., Wang, Y., Xu, H., Zilfou, J.T., Knudsen, K.E., Aronow, B.J., Lowe, S.W. and Knudsen, E.S. (2007) The retinoblastoma tumor suppressor modifies the therapeutic response of breast cancer. The Journal of Clinical Investigation, 117, 218-228. http://dx.doi.org/10.1172/JCI28803
Thangavel, C., Dean, J.L., Ertel, A., Knudsen, K.E., Aldaz, C.M., Witkiewicz, A.K., Clarke, R. and Knudsen, E.S. (2011) Therapeutically activating RB: Reestablishing cell cycle control in endocrine therapy-resistant breast cancer. Endocrine-Related Cancer, 18, 333-345. http://dx.doi.org/10.1530/ERC-10-0262
Miller, T.W., Balko, J.M., Fox, E.M., Ghazoui, Z., Dunbier, A., Anderson, H., Dowsett, M., Jiang, A., Smith, R.A., Maira, S.-M., Manning, H.C., González-Angulo, A.M., Mills, G.B., Higham, C., Chanthaphaychith, S., Kuba, M.G., Miller, W.R., Shyr, Y. and Arteaga, C.L. (2011) ERα-dependent E2F transcription can mediate resistance to estrogen deprivation in human breast cancer. Cancer Discovery, 1, 338-351. http://dx.doi.org/10.1158/2159-8290.CD-11-0101
Bosco, E.E. and Knudsen, E.S. (2007) RB in breast cancer: The crossroads of tumorigenesis and treatment. Cell Cycle, 6, 667-671. http://dx.doi.org/10.4161/cc.6.6.3988
Cavailles, V., Dauvois, S., Danielian, P.S. and Parker, M.G. (1994) Interaction of proteins with transcriptionally active estrogen receptors. Proceedings of the National Academy of Sciences of the United States of America, 91, 10009-10013. http://dx.doi.org/10.1073/pnas.91.21.10009
Cavailles, V., Dauvois, S., L’Horset, F., Lopez, G., Hoare, S., Kushner, P.J. and Parker, M.G. (1995) Nuclear factor RIP140 modulates transcriptional activation by the estrogen receptor. EMBO Journal, 14, 3741-3751.
Castet, A., Boulahtouf, A., Versini, G., Bonnet, S., Augereau, P., Vignon, F., Khochbin, S., Jalaguier, S. and Cavailles, V. (2004) Multiple domains of the receptor-interacting protein 140 contribute to transcription inhibittion. Nucleic Acids Research, 32, 1957-1966. http://dx.doi.org/10.1093/nar/gkh524
Christian, M., Tullet, J.M. and Parker, M.G. (2004) Characterization of four autonomous repression domains in the corepressor receptor interacting protein 140. The Journal of Biological Chemistry, 279, 15645-15651. http://dx.doi.org/10.1074/jbc.M313906200
Wei, L.N., Hu, X., Chandra, D., Seto, E. and Farooqui, M. (2000) Receptor-interacting protein 140 directly recruits histone deacetylases for gene silencing. The Journal of Biological Chemistry, 275, 40782-40787. http://dx.doi.org/10.1074/jbc.M004821200
Vo, N., Fjeld, C. and Goodman, R.H. (2001) Acetylation of nuclear hormone receptor-interacting protein RIP140 regulates binding of the transcriptional corepressor CtBP. Molecular and Cellular Biology, 21, 6181-6188. http://dx.doi.org/10.1128/MCB.21.18.6181-6188.2001
Rytinki, M.M. and Palvimo, J.J. (2008) SUMOylation modulates the transcription repressor function of RIP140. The Journal of Biological Chemistry, 283, 11586-11595. http://dx.doi.org/10.1074/jbc.M709359200
Ho, P.-C., Lin, Y.-W., Tsui, Y.-C., Gupta, P. and Wei, L.-N. (2009) A negative regulatory pathway of GLUT4 trafficking in adipocyte: New function of RIP140 in the cytoplasm via AS160. Cell Metabolism, 10, 516-523. http://dx.doi.org/10.1016/j.cmet.2009.09.012
Ho, P.-C., Chuang, Y.-S., Hung, C.-H. and Wei, L.-N. (2011) Cytoplasmic receptor-interacting protein 140 (RIP140) interacts with perilipin to regulate lipolysis. Cellular Signalling, 23, 1396-1403. http://dx.doi.org/10.1016/j.cellsig.2011.03.023
Kumar, M.B., Tarpey, R.W. and Perdew, G.H. (1999) Differential recruitment of coactivator RIP140 by Ah and estrogen receptors. Absence of a role for LXXLL motifs. The Journal of Biological Chemistry, 274, 22155-22164. http://dx.doi.org/10.1074/jbc.274.32.22155
Zschiedrich, I., Hardeland, U., Krones-Herzig, A., Berriel, D.M., Vegiopoulos, A., Müggenburg, J., Sombroek, D., Hofmann, T.G., Zawatzky, R., Yu, X., Gretz, N., Christian, M., White, R., Parker, M.G. and Herzig, S. (2008) Coactivator function of RIP140 for NFkappaB/RelA-dependent cytokine gene expression. Blood, 112, 264-276. http://dx.doi.org/10.1182/blood-2007-11-121699
Nautiyal, J., Christian, M. and Parker, M.G. (2013) Distinct functions for RIP140 in development, inflammation, and metabolism. Trends in Endocrinology & Metabolism, in press. http://dx.doi.org/10.1016/j.tem.2013.05.001
Ho, P.-C. and Wei, L.-N. (2012) Biological activities of receptor-interacting protein 140 in adipocytes and metabolic diseases. Current Diabetes Reviews, 8, 452-457. http://dx.doi.org/10.2174/157339912803529922
Heery, D.M., Kalkhoven, E., Hoare, S. and Parker, M.G. (1997) A signature motif in transcriptional co-activators mediates binding to nuclear receptors. Nature, 387, 733-736.
Laganière, J., Deblois, G. and Giguère, V. (2005) Functional genomics identifies a mechanism for estrogen activation of the retinoic acid receptor alpha1 gene in breast cancer cells. Molecular Endocrinology, 19, 1584-1592. http://dx.doi.org/10.1210/me.2005-0040
Madak-Erdogan, Z., Charn, T.-H., Jiang, Y., Liu, E.T., Katzenellenbogen, J.A. and Katzenellenbogen, B.S. (2013) Integrative genomics of gene and metabolic regulation by estrogen receptors α and β, and their coregulators. Molecular Systems Biology, 9, Article ID: 676. http://dx.doi.org/10.1038/msb.2013.28
Warnmark, A., Almlof, T., Leers, J., Gustafsson, J.A. and Treuter, E. (2001) Differential recruitment of the mammalian mediator subunit TRAP220 by estrogen receptors ERalpha and ERbeta. The Journal of Biological Chemistry, 276, 23397-23404. http://dx.doi.org/10.1074/jbc.M011651200
Kouzu-Fujita, M., Mezaki, Y., Sawatsubashi, S., Matsumoto, T., Yamaoka, I., Yano, T., Taketani, Y., Kitagawa, H. and Kato, S. (2009) Coactivation of estrogen receptor beta by gonadotropin-induced cofactor GIOT-4. Molecular and Cellular Biology, 29, 83-92. http://dx.doi.org/10.1128/MCB.00884-08
Garcia-Pedrero, J.M., Del Rio, B., Martinez-Campa, C., Muramatsu, M., Lazo, P.S. and Ramos, S. (2002) Calmodulin is a selective modulator of estrogen receptors. Molecular Endocrinology, 16, 947-960. http://dx.doi.org/10.1210/me.16.5.947
García-Pedrero, J.M., Kiskinis, E., Parker, M.G. and Belandia, B. (2006) The SWI/SNF chromatin remodeling subunit BAF57 is a critical regulator of estrogen receptor function in breast cancer cells. The Journal of Biological Chemistry, 281, 22656-22664. http://dx.doi.org/10.1074/jbc.M602561200
Nassa, G., Tarallo, R., Guzzi, P.H., Ferraro, L., Cirillo, F., Ravo, M., Nola, E., Baumann, M., Nyman, T.A., Cannataro, M., Ambrosino, C. and Weisz, A. (2011) Comparative analysis of nuclear estrogen receptor alpha and beta interactomes in breast cancer cells. Molecular BioSystems, 7, 667-676. http://dx.doi.org/10.1039/c0mb00145g
Docquier, A., Garcia, A., Savatier, J., Boulahtouf, A., Bonnet, S., Bellet, V., Busson, M., Jalaguier, S., Margeat, E., Royer, C., Balaguer, P. and Cavailles, V. (2013) Negative regulation of estrogen signaling by ERbeta and RIP140 in ovarian cancer cells. Molecular Endocrinology, 27, 1429-1441.
Porter, W., Saville, B., Hoivik, D. and Safe, S. (1997) Functional synergy between the transcription factor Sp1 and the estrogen receptor. Molecular Endocrinology, 11, 1569-1580. http://dx.doi.org/10.1210/me.11.11.1569
Safe, S. (2001) Transcriptional activation of genes by 17 beta-estradiol through estrogen receptor-Sp1 interactions. Vitamins & Hormones, 62, 231-252.
Teyssier, C., Belguise, K., Galtier, F., Cavailles, V. and Chalbos, D. (2003) Receptor-interacting protein 140 binds c-jun and inhibits estradiol-induced activator protein-1 activity by reversing glucocorticoid receptor-interacting protein 1 effect. Molecular Endocrinology, 17, 287-299. http://dx.doi.org/10.1210/me.2002-0324
Suzuki, A., Sanda, N., Miyawaki, Y., Fujimori, Y., Yamada, T., Takagi, A., Murate, T., Saito, H. and Kojima, T. (2010) Down-regulation of PROS1 gene expression by 17beta-estradiol via estrogen receptor alpha (ERalpha)-Sp1 interaction recruiting receptor-interacting protein 140 and the corepressor-HDAC3 complex. The Journal of Biological Chemistry, 285, 13444-13453. http://dx.doi.org/10.1074/jbc.M109.062430
Ohtake, F., Fujii-Kuriyama, Y. and Kato, S. (2009) AhR acts as an E3 ubiquitin ligase to modulate steroid receptor functions. Biochemical Pharmacology, 77, 474-484. http://dx.doi.org/10.1016/j.bcp.2008.08.034
Reen, R.K., Cadwallader, A. and Perdew, G.H. (2002) The subdomains of the transactivation domain of the aryl hydrocarbon receptor (AhR) inhibit AhR and estrogen receptor transcriptional activity. Archives of Biochemistry and Biophysics, 408, 93-102. http://dx.doi.org/10.1016/S0003-9861(02)00518-0
Madak-Erdogan, Z. and Katzenellenbogen, B.S. (2012) Aryl hydrocarbon receptor modulation of estrogen recaptor α-mediated gene regulation by a multimeric chromatin complex involving the two receptors and the coregulator RIP140. Toxicological Sciences, 125, 401-411. http://dx.doi.org/10.1093/toxsci/kfr300
Docquier, A., Harmand, P.-O., Fritsch, S., Chanrion, M., Darbon, J.-M. and Cavaillès, V. (2010) The transcriptional coregulator RIP140 represses E2F1 activity and discriminates breast cancer subtypes. Clinical Cancer Research, 16, 2959-2970. http://dx.doi.org/10.1158/1078-0432.CCR-09-3153
Hu, Z., Fan, C., Oh, D.S., Marron, J.S., He, X., Qaqish, B.F., Livasy, C., Carey, L.A., Reynolds, E., Dressler, L., Nobel, A., Parker, J., Ewend, M.G., Sawyer, L.R., Wu, J., Liu, Y., Nanda, R., Tretiakova, M., Ruiz Orrico, A., Dreher, D., Palazzo, J.P., Perreard, L., Nelson, E., Mone, M., Hansen, H., Mullins, M., Quackenbush, J.F., Ellis, M.J., Olopade, O.I., Bernard, P.S. and Perou, C.M. (2006) The molecular portraits of breast tumors are conserved across microarray platforms. BMC Genomics, 7, 96. http://dx.doi.org/10.1186/1471-2164-7-96
Katsanis, N., Ives, J.H., Groet, J., Nizetic, D. and Fisher, E.M. (1998) Localisation of receptor interacting protein 140 (RIP140) within 100 kb of D21S13 on 21q11, a gene-poor region of the human genome. Human Genetics, 102, 221-223. http://dx.doi.org/10.1007/s004390050682
Augereau, P., Badia, E., Fuentes, M., Rabenoelina, F., Corniou, M., Derocq, D., Balaguer, P. and Cavailles, V. (2006) Transcriptional regulation of the human NRIP1/ RIP140 gene by estrogen is modulated by dioxin signalling. Molecular Pharmacology, 69, 1338-1346. http://dx.doi.org/10.1124/mol.105.017376
Lee, C.H., Chinpaisal, C. and Wei, L.N. (1998) Cloning and characterization of mouse RIP140, a corepressor for nuclear orphan receptor TR2. Molecular and Cellular Biology, 18, 6745-6755.
Christian, M., White, R. and Parker, M.G. (2006) Metabolic regulation by the nuclear receptor corepressor RIP140. Trends in Endocrinology & Metabolism, 17, 243-250. http://dx.doi.org/10.1016/j.tem.2006.06.008
Jagannathan, V. and Robinson-Rechavi, M. (2011) Metaanalysis of estrogen response in MCF-7 distinguishes early target genes involved in signaling and cell proliferation from later target genes involved in cell cycle and DNA repair. BMC Systems Biology, 5, 138. http://dx.doi.org/10.1186/1752-0509-5-138
Thenot, S., Charpin, M., Bonnet, S. and Cavailles, V. (1999) Estrogen receptor cofactors expression in breast and endometrial human cancer cells. Molecular and Cellular Endocrinology, 156, 85-93. http://dx.doi.org/10.1016/S0303-7207(99)00139-2
Lin, C.-Y., Strom, A., Vega, V.B., Kong, S.L., Yeo, A.L., Thomsen, J.S., Chan, W.C., Doray, B., Bangarusamy, D.K., Ramasamy, A., Vergara, L.A., Tang, S., Chong, A., Bajic, V.B., Miller, L.D., Gustafsson, J.-A. and Liu, E.T. (2004) Discovery of estrogen receptor alpha target genes and response elements in breast tumor cells. Genome Biology, 5, R66. http://dx.doi.org/10.1186/gb-2004-5-9-r66
Carroll, J.S., Liu, X.S., Brodsky, A.S., Li, W., Meyer, C.A., Szary, A.J., Eeckhoute, J., Shao, W., Hestermann, E.V., Geistlinger, T.R., Fox, E.A., Silver, P.A. and Brown, M. (2005) Chromosome-wide mapping of estrogen receptor binding reveals long-range regulation requiring the forkhead protein FoxA1. Cell, 122, 33-43. http://dx.doi.org/10.1016/j.cell.2005.05.008
Escande, A., Pillon, A., Servant, N., Cravedi, J.-P., Larrea, F., Muhn, P., Nicolas, J.-C., Cavaillès, V. and Balaguer, P. (2006) Evaluation of ligand selectivity using reporter cell lines stably expressing estrogen receptor alpha or beta. Biochemical Pharmacology, 71, 1459-1469. http://dx.doi.org/10.1016/j.bcp.2006.02.002
Monroe, D.G., Getz, B.J., Johnsen, S.A., Riggs, B.L., Khosla, S. and Spelsberg, T.C. (2003) Estrogen receptor isoform-specific regulation of endogenous gene expression in human osteoblastic cell lines expressing either ERalpha or ERbeta. Journal of Cellular Biochemistry, 90, 315-326. http://dx.doi.org/10.1002/jcb.10633
Stossi, F., Barnett, D.H., Frasor, J., Komm, B., Lyttle, C.R. and Katzenellenbogen, B.S. (2004) Transcriptional profiling of estrogen-regulated gene expression via estrogen receptor (ER) alpha or ERbeta in human osteosarcoma cells: Distinct and common target genes for these receptors. Endocrinology, 145, 3473-3486. http://dx.doi.org/10.1210/en.2003-1682
Docquier, A., Augereau, P., Lapierre, M., Harmand, P.-O., Badia, E., Annicotte, J.-S., Fajas, L. and Cavaillès, V. (2012) The RIP140 gene is a transcriptional target of E2F1. PloS One, 7, e35839. http://dx.doi.org/10.1371/journal.pone.0035839
Bagamasbad, P. and Denver, R.J. (2011) Mechanisms and significance of nuclear receptor auto-and cross-regulation. General and Comparative Endocrinology, 170, 3-17. http://dx.doi.org/10.1016/j.ygcen.2010.03.013
Safe, S., Wang, F., Porter, W., Duan, R. and McDougal, A. (1998) Ah receptor agonists as endocrine disruptors: Antiestrogenic activity and mechanisms. Toxicology Letters, 102-103, 343-347. http://dx.doi.org/10.1016/S0378-4274(98)00331-2
Swedenborg, E. and Pongratz, I. (2010) AhR and ARNT modulate ER signaling. Toxicology, 268, 132-138. http://dx.doi.org/10.1016/j.tox.2009.09.007
Kerley, J.S., Olsen, S.L., Freemantle, S.J. and Spinella, M.J. (2001) Transcriptional activation of the nuclear receptor corepressor RIP140 by retinoic acid: A potential negative-feedback regulatory mechanism. Biochemical and Biophysical Research Communications, 285, 969-975. http://dx.doi.org/10.1006/bbrc.2001.5274
White, K.A., Yore, M.M., Deng, D. and Spinella, M.J. (2005) Limiting effects of RIP140 in estrogen signaling: potential mediation of anti-estrogenic effects of retinoic acid. The Journal of Biological Chemistry, 280, 7829-7835. http://dx.doi.org/10.1074/jbc.M412707200
Lin, R. (2002) Expression profiling in squamous carcinoma cells reveals pleiotropic effects of vitamin D3 analog EB1089 signaling on cell proliferation, differentiation, and immune system regulation. Molecular Endocrinology, 16, 1243-1256. http://dx.doi.org/10.1210/me.16.6.1243
Graham, J.D., Yager, M.L., Hill, H.D., Byth, K., O’Neill, G.M. and Clarke, C.L. (2005) Altered progesterone receptor isoform expression remodels progestin responsiveness of breast cancer cells. Molecular Endocrinology, 19, 2713-2735. http://dx.doi.org/10.1210/me.2005-0126
Carascossa, S., Gobinet, J., Georget, V., Lucas, A., Badia, E., Castet, A., White, R., Nicolas, J.-C., Cavaillès, V. and Jalaguier, S. (2006) Receptor-interacting protein 140 is a repressor of the androgen receptor activity. Molecular Endocrinology, 20, 1506-1518. http://dx.doi.org/10.1210/me.2005-0286
Nichol, D., Christian, M., Steel, J.H., White, R. and Parker, M.G. (2006) RIP140 expression is stimulated by estrogen-related receptor alpha during adipogenesis. The Journal of Biological Chemistry, 281, 32140-32147. http://dx.doi.org/10.1074/jbc.M604803200
Loh, Y.N., Hedditch, E.L., Baker, L.A., Jary, E., Ward, R.L. and Ford, C.E. (2013) The Wnt signalling pathway is upregulated in an in vitro model of acquired tamoxifen resistant breast cancer. BMC Cancer, 13, 174. http://dx.doi.org/10.1186/1471-2407-13-174
Berger, C., Qian, Y. and Chen, X. (2013) The p53-estrogen receptor loop in cancer. Current Molecular Medicine, in press.